A Study of AZD0486 for B-Cell Malignancies
Phase 1/2
276
about 3.1 years
18+
12 sites in MA, NC, NJ +6
What this study is about
Researchers are testing the safety and effectiveness of AZD0486, either alone or with other cancer drugs, in people with certain types of lymphoma. The trial will last about 1 year and involve a total of approximately 276 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD0486
- 2.Take Acalabrutinib
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
acalabrutinib, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
oral (Oral Capsule), infusion, oral
Primary: Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest, Number of Participants with Dose Limiting Toxicity (DLTs)
Secondary: Area Under the Concentration-time Curve (AUC), Clearance (CL) of surovatamig, Complete Response (CR) Rate, Duration of Response (DoR), Half Life (t1/2) of surovatamig, Maximum Observed Concentration (Cmax), Overall Response Rate (ORR), Time to Reach Maximum Concentration (tmax)
Oncology